Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $33.59 USD
Change Today -0.77 / -2.24%
Volume 418.2K
MYGN On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mark Christopher Capone

President of Myriad Genetic Laboratories, Myriad Genetics Inc.
AgeTotal Calculated CompensationThis person is connected to 15 board members in 1 different organizations across 3 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Mark Christopher Capone has been the President of Myriad Genetic Laboratories at Myriad Genetics Inc. since March 1, 2010. Mr. Capone served as the Chief Operating Officer of Myriad Genetic Laboratories Inc. at Myriad Genetics Inc. since February, 2006. He served as Senior Vice President of Sales at Myriad Genetics Inc. from October 2002 to 2006. He joined Myriad Genetics in October 2002. Prior to joining Myriad, Mr. Capone served 17 years with Eli Lilly and Company, ...

Read Full Background

Corporate Headquarters*

320 Wakara Way
Salt Lake City, Utah 84108

United States

Phone: 801-584-3600
Fax: 801-584-3640

Board Members Memberships*

Director, Member of Audit Committee and Member of Nominating & Governance Committee


MS 1991
Massachusetts Institute of Technology
BS 1984
Pennsylvania State University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$567,976

Stock Options*

All Other Compensation$10,248
Exercised Options182,750
Exercised Options Value$3,062,393
Exercisable Options443,672
Exercisable Options Value$5,847,574
Unexercisable Options741,250
Unexercisable Options Value$10,392,890
Total Value of Options$19,302,857
Total Number of Options1,367,672

Total Compensation*

Total Annual Cash Compensation$1,130,224
Total Short Term Compensation$567,976
Other Long Term Compensation$10,248
Total Calculated Compensation$4,512,064
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $33.59 USD -0.77


Joseph A. Chlapaty Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Advanced Drainage Systems, Inc.
Marc D. Grodman M.D.Founder, Chairman, Chief Executive Officer, President and Managing Director
Bio-Reference Laboratories Inc.
Howard G. Berger M.D.Chairman, Chief Executive Officer, President and Treasurer
RadNet, Inc.
Percy C. Tomlinson Jr.Chief Executive Officer, President and Director
Alliance Healthcare Services, Inc.
Kimberly J. Popovits Chairman of the Board, Chief Executive Officer, President and Member of Non-Management Stock Option Committee
Genomic Health Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at